CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin
Biotechnology and Bioengineering · 2025
DOI: 10.1002/bit.29028 ↗At a glance
Journal article in Biotechnology and Bioengineering, 2025. Written by Jackson K B Cahn and 9 co-authors. Institution: Process Research & Development, Merck & Co. Inc., Rahway, New Jersey, USA. Major MEDLINE topics: Gene Editing, Fibronectins, CRISPR-Cas Systems, Viral Vaccines. Cited 2 times so far (Crossref); 31 references.
Abstract (original language)
Removal of host cell components is a significant cost driver in the production of live virus vaccines. Filtration processes such as tangential flow filtration can be effective in this capacity by leveraging the relative size difference between viral particles and host proteins; however, filtration membranes can be fouled by larger proteins, particularly those of the extracellular matrix. In this study, we used CRISPR editing to insert the recognition element of the highly‐selective TEV protease into various positions of the gene encoding fibronectin in the genome of the Vero cell line, a common platform for viral production. By screening edited cell lines, we identified a promising candidate line in which fibronectin could be effectively removed by treating with the protease during processing, eliminating filter fouling and allowing for viral purification without the need for costly chromatography steps.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Process Research & Development, Merck & Co. Inc., Rahway, New Jersey, USA.
- Process Research & Development, Merck & Co. Inc., West Point, Pennsylvania, USA.
- Analytical Research & Development, Merck & Co. Inc., West Point, Pennsylvania, USA.
ORCID profiles: Jackson K B Cahn, Jeffrey Moore
Cite
APA
Cahn, J. K. B., Ludwicki, H., Shingler, J., Gulvin, S., Zhang, Y., Kristopeit, A., Ton, C., Winters, M. A., Wagner, J. M., & Moore, J. (2025). CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.29028
Vancouver
Cahn JKB, Ludwicki H, Shingler J, Gulvin S, Zhang Y, Kristopeit A, et al. CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin. Biotechnology and Bioengineering. 2025. doi:10.1002/bit.29028
BibTeX
@article{Cahn2025,
author = {Cahn, Jackson K B and Ludwicki, Henry and Shingler, Jillian and Gulvin, Shannon and Zhang, Young and Kristopeit, Adam and Ton, Christopher and Winters, Michael A and Wagner, James M and Moore, Jeffrey},
title = {CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin},
journal = {Biotechnology and Bioengineering},
year = {2025},
doi = {10.1002/bit.29028}
}
EUVIMED